T. Rowe Price Drops on Earnings Miss as Options Traders Turn Defensive

T. Rowe Price Group reported quarterly results this week that fell short of expectations, the shares slid 2.6% on Friday to $103.90, and the options market moved sharply toward downside protection in a way it hasn't all year.

The options shift is the sharpest signal in the data. The put/call ratio closed at 1.05, more than two standard deviations above its 20-day average of 0.82. That's the most defensive options positioning of the past 12 months outside of the 52-week high of 1.44. The move didn't emerge gradually: as recently as October 22, the ratio was sitting at 0.79, squarely in line with trend. The jump happened in the four sessions surrounding the earnings release, which reported average AUM declining and a core fee rate of 0.396%, marginally below what analysts had pencilled in.

Short interest tells a less alarming story. Shorts hold 11.7% of the free float, a structurally elevated number for an asset manager, but the position actually contracted 5.1% over the past week to roughly 25.4 million shares. The borrow market remains loose: availability runs at 304%, meaning there are three shares available to borrow for every one already lent out, well above the 52-week low of 234%. Borrowing costs are effectively negligible at 0.53%, up about 8% on the week but still at a level that imposes no friction on new shorts. So the bears are not adding aggressively; if anything, they have been trimming into the selloff.

Analyst reaction to the results was mixed rather than uniformly negative. TD Cowen's Bill Katz cut his target sharply from $109 to $96, the most bearish move on the sheet. JP Morgan raised its target by $1 to $107 while keeping an Underweight rating, a gesture more than a conviction call. Morgan Stanley lifted its target to $112 last week before the print. KBW nudged its target to $113. The mean target across the Street sits at $106, within earshot of the current price. No firm upgraded the stock. The direction of travel is neutral to cautious: most analysts cluster around market-perform equivalents, and the EV/EBITDA multiple has drifted up modestly over 30 days to 6.7, partly because earnings came in softer. The factor profile underscores the tension. Dividend score ranks in the 90th percentile, and the earnings yield and EV/EBIT scores are both healthy. EPS momentum, however, ranks in the 24th to 29th percentile on both 30- and 90-day views, reflecting the persistent pressure on AUM-linked fees.

One data point worth noting on the company's own activity: T. Rowe bought back $167.3 million of its own shares in the second quarter of 2026, up 48% from the same quarter a year earlier and the largest Q2 buyback spend in three years, per SEC EDGAR XBRL filings collated by ORTEX. That kind of capital return at current prices is a mechanical floor argument, though the buyback data covers a period that ended before this week's drop. Wikipedia page views and ORTEX stock page traffic have also spiked, with retail attention running roughly two standard deviations above its own 90-day history as of October 22, a reflection of the earnings event rather than a revenue indicator.

Insider activity over the 90-day window is net negative at roughly $1.1 million sold. The most recent filings show a director exercising options at $62.85 on October 27, a compensation-related transaction that carries little informational weight. The September cluster of director stock awards at $104.51 are routine grant transactions rather than open-market conviction buys. Institutional holders are stable: BlackRock added 1.2 million shares in the most recent period to reach 11.2% of shares, and Charles Schwab Investment Management added 478,000 shares. No activist is on the 13D register.

The stock underperformed its peer group sharply this week. APAM rose 9.0% over the same period, BCSF added 7.0%, and VRTS was near flat despite falling 5.4% on Friday. TROW's week-on-week move of negative 0.3% looks resilient against those Friday closes, but the gap to APAM and BCSF suggests the market is rewarding asset managers with cleaner AUM momentum. The next earnings event is not until February 5, 2027, leaving the question of whether AUM trends stabilise or deteriorate through Q4 as the primary factor to track over the coming months.